Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

GE Healthcare’s PET project

This article was originally published in The Gray Sheet

Executive Summary

Hammersmith Hospital in London is enrolling subjects for GE's first-in-man clinical study evaluating the use of a positron emission tomography (PET) agent to detect the location and growth patterns of tumors. According to a June 5 release, the imaging agent has a biological mechanism to track angiogenesis, or the formation of new blood vessels in the body, necessary for the growth of many tumors. The study will quantify response to therapy by imaging Stage IV metastatic tumors of the breast before and after cycles of chemotherapy. A recent report on FDA's Critical Path initiative highlighted the role for imaging in developing cancer products (1"The Gray Sheet" March 27, 2006, p. 5). GE says it is "looking forward to collaborating with the pharmaceutical industry to enable more targeted therapies"...
Advertisement

Related Content

Advertisement
UsernamePublicRestriction

Register

MT023653

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel